SEB Asset Management AB Purchases New Position in Zimmer Biomet Holdings, Inc. $ZBH

SEB Asset Management AB acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 39,524 shares of the medical equipment provider’s stock, valued at approximately $3,574,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. DV Equities LLC bought a new stake in Zimmer Biomet in the fourth quarter worth approximately $25,000. Monetary Solutions Ltd bought a new position in shares of Zimmer Biomet during the 4th quarter valued at $30,000. Gen Wealth Partners Inc acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at $31,000. Flagship Harbor Advisors LLC bought a new stake in Zimmer Biomet in the fourth quarter worth $32,000. Finally, Cornerstone Financial Management LLC bought a new stake in Zimmer Biomet in the fourth quarter worth $37,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $88.79 on Thursday. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. The company has a market cap of $17.18 billion, a price-to-earnings ratio of 23.06, a PEG ratio of 2.62 and a beta of 0.46. The firm’s 50-day moving average is $87.61 and its 200-day moving average is $89.80.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating the consensus estimate of $1.86 by $0.23. The firm had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Thursday, June 25th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is 24.94%.

Analyst Ratings Changes

ZBH has been the topic of several recent research reports. Canaccord Genuity Group set a $83.00 target price on Zimmer Biomet in a report on Wednesday, April 29th. Citizens Jmp lowered their price objective on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a report on Wednesday, April 29th. Wall Street Zen downgraded Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. JPMorgan Chase & Co. reduced their target price on Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a report on Wednesday, April 29th. Finally, Truist Financial reaffirmed a “hold” rating and set a $92.00 target price (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and a consensus price target of $100.70.

Insiders Place Their Bets

In other news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.28% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.